NBTX vs MRK vs BMY vs PFE

For growth investors, Merck & Co.

, Inc. (MRK) is the stronger pick with 1. 2% revenue growth year-over-year, versus -132. 1% for Nanobiotix S. A. (NBTX). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Nanobiotix S. A. (NBTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus Pfizer Inc. at 19. 5x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Nanobiotix S.

A. (NBTX) delivered a total return of +182. 9%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: NBTX returned +167. 9% versus BMY's +6. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 45β versus Nanobiotix S. A. 's 2. 09β — meaning NBTX is approximately 359% more volatile than MRK relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Merck & Co.

, Inc. (MRK) is pulling ahead at 1. 2% versus -132. 1% for Nanobiotix S. A. (NBTX). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -33. 3% for Nanobiotix S. A.. Over a 3-year CAGR, MRK leads at 3. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nanobiotix S.

A. (NBTX) is the more profitable company, earning 586. 9% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 586. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBTX leads at 589. 1% versus 24. 7% for PFE. At the gross margin level — before operating expenses — NBTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.

9x forward P/E versus 21. 9x for Merck & Co. , Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MRK: 15. 2% to $129. 31.

In this comparison, PFE (6.

5% yield), BMY (4. 4% yield), MRK (2. 9% yield) pay a dividend. NBTX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Nanobiotix S. A. (NBTX) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +164. 7%, NBTX: +167. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NBTX is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock. MRK, BMY, PFE pay a dividend while NBTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.